Cargando…

Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance

BACKGROUND: Vascular dementia (VAD) is the second most common type of dementia lacking effective treatments. Pentoxifylline (PTX), a nonselective phosphodiesterase inhibitor, displays protective effects in multiple cerebral diseases. In this study, we aimed to investigate the therapeutic effects and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Lili, Jia, Junqiu, Chen, Yan, Liu, Renyuan, Cao, Runjing, Duan, Manlin, Zhang, Meijuan, Xu, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153105/
https://www.ncbi.nlm.nih.gov/pubmed/35642056
http://dx.doi.org/10.1186/s12974-022-02480-4
_version_ 1784717780408336384
author Zheng, Lili
Jia, Junqiu
Chen, Yan
Liu, Renyuan
Cao, Runjing
Duan, Manlin
Zhang, Meijuan
Xu, Yun
author_facet Zheng, Lili
Jia, Junqiu
Chen, Yan
Liu, Renyuan
Cao, Runjing
Duan, Manlin
Zhang, Meijuan
Xu, Yun
author_sort Zheng, Lili
collection PubMed
description BACKGROUND: Vascular dementia (VAD) is the second most common type of dementia lacking effective treatments. Pentoxifylline (PTX), a nonselective phosphodiesterase inhibitor, displays protective effects in multiple cerebral diseases. In this study, we aimed to investigate the therapeutic effects and potential mechanisms of PTX in VAD. METHODS: Bilateral common carotid artery stenosis (BCAS) mouse model was established to mimic VAD. Mouse behavior was tested by open field test, novel object recognition test, Y-maze and Morris water maze (MWM) tests. Histological staining, magnetic resonance imaging (MRI) and electron microscopy were used to define white matter integrity. The impact of PTX on microglia phagocytosis, peroxisome proliferator-activated receptors-γ (PPAR-γ) activation and Mer receptor tyrosine kinase (Mertk) expression was assessed by immunofluorescence, western blotting and flow cytometry with the application of microglia-specific Mertk knockout mice, Mertk inhibitor and PPAR-γ inhibitor. RESULTS: Here, we found that PTX treatment alleviated cognitive impairment in novel object recognition test, Y-maze and Morris water maze tests. Furthermore, PTX alleviated white matter injury in corpus callosum (CC) and internal capsule (IC) areas as shown by histological staining and MRI analysis. PTX-treatment group presented thicker myelin sheath than vehicle group by electron microscopy. Mechanistically, PTX facilitated microglial phagocytosis of myelin debris by up-regulating the expression of Mertk in BCAS model and primary cultured microglia. Importantly, microglia-specific Mertk knockout blocked the therapeutic effects of PTX in BCAS model. Moreover, Mertk expression was regulated by the nuclear translocation of PPAR-γ. Through modulating PPAR-γ, PTX enhanced Mertk expression. CONCLUSIONS: Collectively, our results demonstrated that PTX showed therapeutic potentials in VAD and alleviated ischemic white matter injury via modulating Mertk-mediated myelin clearance in microglia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02480-4.
format Online
Article
Text
id pubmed-9153105
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-91531052022-06-01 Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance Zheng, Lili Jia, Junqiu Chen, Yan Liu, Renyuan Cao, Runjing Duan, Manlin Zhang, Meijuan Xu, Yun J Neuroinflammation Research BACKGROUND: Vascular dementia (VAD) is the second most common type of dementia lacking effective treatments. Pentoxifylline (PTX), a nonselective phosphodiesterase inhibitor, displays protective effects in multiple cerebral diseases. In this study, we aimed to investigate the therapeutic effects and potential mechanisms of PTX in VAD. METHODS: Bilateral common carotid artery stenosis (BCAS) mouse model was established to mimic VAD. Mouse behavior was tested by open field test, novel object recognition test, Y-maze and Morris water maze (MWM) tests. Histological staining, magnetic resonance imaging (MRI) and electron microscopy were used to define white matter integrity. The impact of PTX on microglia phagocytosis, peroxisome proliferator-activated receptors-γ (PPAR-γ) activation and Mer receptor tyrosine kinase (Mertk) expression was assessed by immunofluorescence, western blotting and flow cytometry with the application of microglia-specific Mertk knockout mice, Mertk inhibitor and PPAR-γ inhibitor. RESULTS: Here, we found that PTX treatment alleviated cognitive impairment in novel object recognition test, Y-maze and Morris water maze tests. Furthermore, PTX alleviated white matter injury in corpus callosum (CC) and internal capsule (IC) areas as shown by histological staining and MRI analysis. PTX-treatment group presented thicker myelin sheath than vehicle group by electron microscopy. Mechanistically, PTX facilitated microglial phagocytosis of myelin debris by up-regulating the expression of Mertk in BCAS model and primary cultured microglia. Importantly, microglia-specific Mertk knockout blocked the therapeutic effects of PTX in BCAS model. Moreover, Mertk expression was regulated by the nuclear translocation of PPAR-γ. Through modulating PPAR-γ, PTX enhanced Mertk expression. CONCLUSIONS: Collectively, our results demonstrated that PTX showed therapeutic potentials in VAD and alleviated ischemic white matter injury via modulating Mertk-mediated myelin clearance in microglia. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12974-022-02480-4. BioMed Central 2022-05-31 /pmc/articles/PMC9153105/ /pubmed/35642056 http://dx.doi.org/10.1186/s12974-022-02480-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zheng, Lili
Jia, Junqiu
Chen, Yan
Liu, Renyuan
Cao, Runjing
Duan, Manlin
Zhang, Meijuan
Xu, Yun
Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance
title Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance
title_full Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance
title_fullStr Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance
title_full_unstemmed Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance
title_short Pentoxifylline alleviates ischemic white matter injury through up-regulating Mertk-mediated myelin clearance
title_sort pentoxifylline alleviates ischemic white matter injury through up-regulating mertk-mediated myelin clearance
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9153105/
https://www.ncbi.nlm.nih.gov/pubmed/35642056
http://dx.doi.org/10.1186/s12974-022-02480-4
work_keys_str_mv AT zhenglili pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance
AT jiajunqiu pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance
AT chenyan pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance
AT liurenyuan pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance
AT caorunjing pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance
AT duanmanlin pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance
AT zhangmeijuan pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance
AT xuyun pentoxifyllinealleviatesischemicwhitematterinjurythroughupregulatingmertkmediatedmyelinclearance